A public body that develops and provides guidance to UK healthcare professionals and others, to ensure that the care they provide is of the best possible quality and offers the best value for money.
The NHS must adopt new budget strategies to research and manufacture cell and gene therapies of the future, according to a recent report...
A new gene therapy, Casgevy, has been recommended for use on the NHS in England for people living with a severe form of beta-thalassaemia...
PET marks the second anniversary of the Women's Health Strategy by launching the PET Fertility Policy Tracker – a simple to use and free to access tracker of ICBs' fertility policies in England...
A new gene therapy for haemophilia B is to be made available for NHS patients after approval from the UK's National Institute for Health and Care Excellence.
The meticulous scrutiny of the efficacy and cost-effectiveness of medical treatments and procedure by NICE is put into question by Professor Dusko Ilic when comparing the use of cryopreserved ovarian tissue and testicular tissue for restoration of fertility...
A lesbian couple from Manchester reported they were asked by a GP 'Why don't you just go out and find a man to sleep with?', to have a baby...
The cost of accessing private fertility treatment in England can vary by up to 30 percent, depending on where you live...
The American Society for Reproductive Medicine's decision to expand its definition of infertility to be inclusive of a larger group of individuals and couples seeking to build families, irrespective of sexual orientation or relationship status, aims to maximise both inclusion and access to care…
The National Institute for Health and Care Excellence has recommended the NHS funds olaparib for the maintenance treatment of advanced ovarian cancer in women with BRCA1 and 2 variants and advanced or metastatic prostate cancer in men...
Subscribe for free to what PET does best – informing you of the latest in fertility, genomics and embryo research.
